Oncotarget

Research Papers:

Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer

Bhaskar Bhattacharya, Sarah Hong Hui Low, Mei Ling Chong, Dilys Chia, King Xin Koh, Nur Sabrina Sapari, Stanley Kaye, Huynh Hung, Touati Benoukraf and Richie Soong _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:29187-29198. https://doi.org/10.18632/oncotarget.8692

Metrics: PDF 731 views  |   HTML 1051 views  |   ?  


Abstract

Bhaskar Bhattacharya1, Sarah Hong Hui Low1, Mei Ling Chong1, Dilys Chia2, King Xin Koh3, Nur Sabrina Sapari1, Stanley Kaye4, Huynh Hung5, Touati Benoukraf1, Richie Soong1,3

1Cancer Science Institute of Singapore, National University of Singapore, Singapore

2Department of Pharmacy, National University of Singapore, Singapore

3Department of Pathology, National University of Singapore, Singapore

4Drug Development Unit, Royal Marsden NHS Trust, The Royal Marsden NHS Foundation Trust, London, United Kingdom

5Laboratory of Molecular Endocrinology, National Cancer Centre of Singapore, Singapore

Correspondence to:

Richie Soong, e-mail: richie.soong@nus.edu.sg

Bhaskar Bhattacharya, e-mail: csibbu@nus.edu.sg

Keywords: acquired resistance, combination therapy, MEK inhibitors, PI3K inhibitors, synergy

Received: December 01, 2015     Accepted: March 28, 2016     Published: April 11, 2016

ABSTRACT

Historically, understanding of acquired resistance (AQR) to combination treatment has been based on knowledge of resistance to its component agents. To test whether an altered drug interaction could be an additional factor in AQR to combination treatment, models of AQR to combination and single agent MEK and PI3K inhibitor treatment were generated. Combination indices indicated combination treatment of PI3K and MEK inhibitors remained synergistic in cells with AQR to single agent but not combination AQR cells. Differences were also observed between the models in cellular phenotypes, pathway signaling and drug cross-resistance. Genomics implicated TGFB2-EDN1 overexpression as candidate determinants in models of AQR to combination treatment. Supplementation of endothelin in parental cells converted synergism to antagonism. Silencing of TGFB2 or EDN1 in cells with AQR conferred synergy between PI3K and MEK inhibitor. These results highlight that AQR to combination treatment may develop through alternative mechanisms to those of single agent treatment, including a change in drug interaction.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8692